Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Up 90.1% in April

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 768,300 shares, an increase of 90.1% from the March 31st total of 404,200 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 1,575,100 shares, the short-interest ratio is currently 0.5 days.

Bayer Aktiengesellschaft Price Performance

Shares of BAYRY traded down $0.12 during midday trading on Friday, hitting $6.47. 484,479 shares of the company traded hands, compared to its average volume of 836,219. The stock has a 50-day moving average of $6.15 and a 200-day moving average of $5.80. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.32 and a quick ratio of 0.81. Bayer Aktiengesellschaft has a one year low of $4.79 and a one year high of $8.58. The firm has a market cap of $25.43 billion, a P/E ratio of -24.88 and a beta of 0.93.

Bayer Aktiengesellschaft Increases Dividend

The company also recently declared a dividend, which will be paid on Monday, May 12th. Shareholders of record on Wednesday, April 30th will be issued a $0.0224 dividend. This represents a yield of 0.38%. This is an increase from Bayer Aktiengesellschaft's previous dividend of $0.02. The ex-dividend date is Tuesday, April 29th. Bayer Aktiengesellschaft's dividend payout ratio (DPR) is presently -2.78%.

Wall Street Analysts Forecast Growth

Separately, Hsbc Global Res upgraded Bayer Aktiengesellschaft to a "hold" rating in a research report on Monday.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.